[Featured Stock] HanAll Biopharma Plummets on News of Clinical Trial Halt by US Partner
[Asia Economy Reporter Park Jihwan] On the 3rd, HanAll Biopharma is experiencing a sharp decline of over 26%. This is interpreted as being influenced by the news of the clinical trial suspension by its US partner, Immunovant.
As of 10:25 AM on the same day, HanAll Biopharma's stock price showed a steep drop of 26.68% compared to the previous trading day, reaching 23,500 KRW.
Hot Picks Today
After Topping 8,000 Instead of Hitting 10,000... KOSPI Plunges—When Will It Rebound?
- "Samsung and Hynix Were Once for the Underachievers"... Hyundai Motor Employee's Lament
- [Breaking] Court Rules Against Samsung Electronics Union...1 Billion Won per Day Penalty for Exceeding Strike Scope
- Six Economic Organizations Urge Withdrawal of Samsung Electronics Strike Plan...Warn of National Loss of Opportunity
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
HanAll Biopharma announced that its US partner, Immunovant, decided on the 2nd (local time) to temporarily suspend the administration of the candidate drug 'IMVT-1401' during the Phase 2b clinical trial for thyroid eye disease. Immunovant's stock price also plummeted by 42.08% on the US Nasdaq market.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
